It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alterations in phospholipids have long been associated with spinal cord injury (SCI). However, their specific roles and signaling cascades in mediating cell death and tissue repair remain unclear. Here we investigated whether alterations of cardiolipin (CL), a family of mitochondrion-specific phospholipids, play a crucial role in mitochondrial dysfunction and neuronal death following SCI. Lipidomic analysis was used to determine the profile of CL alteration in the adult rat spinal cord following a moderate contusive SCI at the 10th thoracic (T10) level. Cellular, molecular, and genetic assessments were performed to determine whether CL alterations mediate mitochondrial dysfunction and neuronal death after SCI, and, if so, whether reversing CL alteration leads to neuroprotection after SCI. Using lipidomic analysis, we uncovered CL alterations at an early stage of SCI. Over 50 distinct CL species were identified, of which 50% showed significantly decreased abundance after SCI. The decreased CL species contained mainly polyunsaturated fatty acids that are highly susceptible to peroxidation. In parallel, 4-HNE, a lipid peroxidation marker, significantly increased after SCI. We found that mitochondrial oxidative stress not only induced CL oxidation, but also resulted in CL loss by activating cPLA2 to hydrolyze CL. CL alterations induced mitochondrial dysfunction and neuronal death. Remarkably, pharmacologic inhibition of CL alterations with XJB-5-131, a novel mitochondria-targeted electron and reactive oxygen species scavenger, reduced cell death, tissue damage and ameliorated motor deficits after SCI in adult rats. These findings suggest that CL alteration could be a novel mechanism that mediates injury-induced neuronal death, and a potential therapeutic target for ameliorating secondary SCI.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Indiana University School of Medicine, Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Department of Neurological Surgery, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919)
2 Frontage Laboratories, Exton, USA (GRID:grid.257413.6)
3 Washington University School of Medicine, Department of Medicine, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
4 The Fourth Military Medical University, Department of Anatomy and K.K. Leung Brain Research Centre, Preclinical School of Medicine, Xi’an, P. R. China (GRID:grid.233520.5) (ISNI:0000 0004 1761 4404)
5 The Fourth Military Medical University, Institute of Neuroscience, Xi’an, P. R. China (GRID:grid.233520.5) (ISNI:0000 0004 1761 4404)
6 University of Pittsburgh, Department of Chemistry, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
7 University of Texas Health Science Center at San Antonio, Department of Medicine, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880)